{{{Image1}}}

1. Breast Cancer Awareness: Why It Matters

Breast Cancer Awareness Month is a good reminder to understand breast health, recognise changes early and know which tests may be appropriate for you. The right test is not the same for everyone. Your age, family history, symptoms, breast health, previous findings and individual risk factors can all influence what your doctor recommends.

If you are looking for information about breast cancer screening in Delhi, understanding the purpose of each test can help you discuss the most appropriate testing plan with your doctor.

Breast self-awareness: know what is normal for you

Breast self-awareness means knowing how your breasts normally look and feel so that you can recognise changes. It is not a diagnostic test. Changes that should be evaluated by a doctor include:

A new lump or thickening
Changes in breast size or shape
Skin dimpling or puckering
Nipple retraction
Unusual nipple discharge
Persistent or unexplained breast changes

Screening by age and risk

There is no single breast cancer test that applies to everyone. The USPSTF recommends screening mammography every two years for women aged 40 to 74 at average risk, while the American Cancer Society offers the option of annual screening at 40 to 44 and recommends annual mammography from 45. Women at higher risk may need an individualised plan.

Screening recommendations can vary between organisations and according to individual risk, so discuss the appropriate screening schedule with your healthcare professional.

Age or Risk Group	Test or Evaluation	Purpose
Younger adults	Breast self-awareness; clinical evaluation when indicated	Identifies changes needing medical assessment
Around age 40 onward	Mammography based on individual risk and guidelines	Helps detect abnormalities before they become noticeable
Any age with a new lump or change	Clinical evaluation, mammography or ultrasound as advised	Investigates a new or suspicious finding
Strong family or personal history	Genetic risk assessment, counselling and testing when indicated	Assesses hereditary breast cancer risk
After a breast cancer diagnosis	Imaging, pathology and selected laboratory tests as advised	Supports treatment planning and follow-up

Mammography and ultrasound

Mammogram: an X-ray-based screening tool and an established way to detect breast abnormalities. A normal result does not rule out every breast problem, so new or persistent symptoms should still be evaluated.
Breast ultrasound: uses sound waves to evaluate a specific lump or an abnormality found on another test, and may be used together with mammography. For women with dense breasts, the value of additional ultrasound or MRI after a normal mammogram is still debated.

2. Cancer in General: What Everyone Should Know

Cancer is not one disease. It is a group of diseases in which cells grow abnormally and can spread to other parts of the body. Breast cancer is one of the most common cancers in women, but many cancers share common themes:

Early detection improves options. When cancer is detected at an earlier stage, treatment options and outcomes may be more favourable, although this varies by cancer type and stage.
Risk factors overlap. Age, family history, tobacco and alcohol use, obesity, physical inactivity and certain inherited gene variants can influence the risk of several cancers.
Screening is cancer-specific. A test that is useful for one cancer, such as mammography for breast cancer, does not screen for others.
Symptoms matter. Unexplained lumps, persistent pain, unexplained weight loss, abnormal bleeding or long-standing changes in bowel habits should be medically evaluated.

3. Common Tumour Markers: What Are They?

Tumour markers are substances, often proteins, that may be found in blood in people with certain cancers. Levels can also rise in non-cancerous conditions, so they are used as supportive tools, not standalone diagnostic tests. The Cancer Marker Female profile at Dr. Dangs Lab brings together several commonly used markers:

Marker	Commonly associated with
CA 15.3	Breast cancer
CEA	Colorectal and other cancers, including breast, lung and pancreatic
CA 19.9	Pancreatic and biliary cancers
Alpha-fetoprotein (AFP)	Liver cancer and certain germ cell tumours
Beta hCG	Germ cell tumours and gestational trophoblastic disease
CA 72.4	Gastric cancer, and sometimes ovarian and colorectal cancers
Risk of Ovarian Malignancy	Estimating the likelihood that a pelvic mass is malignant
PIVKA-II / DCP	Liver cancer (hepatocellular carcinoma)

A normal marker does not rule out cancer, and a raised marker does not confirm it. Results must be read together with clinical findings, imaging and other investigations.

4. Breast Cancer Markers: Screening, Recurrence and Treatment

CA 15.3: A Breast Cancer Tumour Marker

CA 15.3 is a blood-based tumour marker associated with breast cancer, and it is available at Dr. Dangs Lab. It is also included in our Cancer Marker Female profile.

Screening: CA 15.3 is not recommended as a routine screening test for people without symptoms, because levels can be normal in early breast cancer and can be raised in non-cancerous conditions.
Recurrence and monitoring: in people already diagnosed with breast cancer, a doctor may track CA 15.3 over time alongside clinical assessment and imaging to help monitor the disease.
Treatment: changes in levels during treatment may be reviewed as one part of the overall picture, never on their own.

A single value is less informative than a trend, so repeat testing at the same laboratory, as advised by your doctor, helps keep comparisons consistent.

Cancer Marker Female: What Does the Panel Include?

The Cancer Marker Female profile at Dr. Dangs Lab is a blood-based panel that includes CEA, CA 19.9, CA 15.3, alpha-fetoprotein, beta hCG, CA 72.4, Risk of Ovarian Malignancy and PIVKA-II/DCP. Together, these markers cover cancers that may affect women, including breast, ovarian, gastrointestinal and liver cancers.

The panel can provide supportive information when a doctor is evaluating symptoms, clinical history or a known condition, or monitoring a person already diagnosed. It is not a standalone screening or diagnostic test for breast cancer or any other cancer, and the results should be interpreted with imaging and other investigations.

FNAC for a breast lump

Blood markers are only one part of breast cancer evaluation. When a lump or suspicious area needs further evaluation, FNAC (Fine Needle Aspiration Cytology) may be recommended. A thin needle collects cells, which a pathologist examines under a microscope. Depending on the findings, your doctor may advise further imaging, repeat sampling or a core biopsy.

Other markers

Your doctor may sometimes consider other breast-related markers such as CA 27.29.

5. Genetic Screening for Hereditary Breast Cancer Risk

Most breast cancers are not inherited, but a smaller proportion are linked to inherited gene variants.

BRCA1 and BRCA2 testing

Not everyone needs a BRCA gene test. It may be considered when there is a significant personal or family history of breast, ovarian or related cancers, or other features suggesting hereditary risk. The USPSTF recommends risk assessment and, when indicated, genetic counselling and testing for people with relevant histories. A positive result does not mean cancer is certain. It indicates an inherited variant associated with increased risk and may influence discussions about screening and risk management.

Comprehensive Hereditary Cancer Gene Panel

In some families, hereditary cancer risk is not explained by BRCA1 or BRCA2 alone. This panel examines multiple genes associated with inherited cancer susceptibility. It may be considered when a doctor or genetic counsellor believes a broader evaluation is appropriate based on personal history, family history or other clinical factors.

Genetic results should always be interpreted with appropriate clinical and genetic counselling.

6. MCD: Multi-Cancer Detection Blood Test

Breast cancer awareness is part of a wider conversation about early detection across cancers. Many cancers have no recommended routine screening test, which is where multi-cancer detection research is focused.

Guardant Health's MCD test has received US FDA breakthrough device designation. The test is intended to detect 10 cancers with a single blood draw.

This test is available through Dr. Dangs Lab, and you can schedule your appointment here. It is a screening test and should be considered alongside clinical evaluation and established cancer-screening guidelines.

Breast Cancer Screening and Testing in Delhi

Dr. Dangs Lab offers pathology and diagnostic investigations that may include CA 15.3, Cancer Marker Female, FNAC, BRCA1 and BRCA2 testing, a Comprehensive Hereditary Cancer Gene Panel, MCD, and other tests advised by your doctor.

Mammography and breast ultrasound are important imaging tools used in breast cancer screening and evaluation. Laboratory tests may provide additional information when recommended based on individual clinical needs.

The appropriate test should be chosen based on individual clinical requirements.

When Should You See a Doctor Without Waiting for Your Next Screening?

Do not wait for your next scheduled screening if you notice a new or concerning breast change. Speak with a doctor if you experience:

A new lump or thickening
Skin dimpling or puckering
Nipple retraction
Unusual or blood-stained nipple discharge
A change in breast size or shape
A persistent or unexplained breast change

Early medical evaluation can help determine whether further examination, imaging or laboratory testing is needed.

Getting the Right Test at the Right Time

Breast cancer screening and evaluation are not limited to one test. Mammography and ultrasound evaluate breast tissue, FNAC provides cellular information about a suspicious lump, and CA 15.3 helps in monitoring people already diagnosed. BRCA testing and hereditary cancer panels assess inherited risk in selected individuals, and MCD offers a blood-based option for multi-cancer screening in eligible individuals.

If you are due for screening, have noticed a breast change or have a family history of breast or ovarian cancer, speak with your doctor about the most appropriate tests for you.

FAQs Around Breast Cancer Test

At what age should breast cancer screening start?

It depends on your risk and the guideline followed. The USPSTF recommends screening mammography every two years for women aged 40 to 74 at average risk, while other organisations recommend different starting ages and intervals.

Is a mammogram enough to detect breast cancer?

Mammography is an important screening tool, but no single test detects every breast abnormality. Additional evaluation may be recommended depending on symptoms, breast density, imaging findings and individual risk.

When is a breast ultrasound recommended?

It may be used to evaluate a specific lump or abnormality and can complement mammography when additional assessment is needed.

Can a Cancer Marker Female test diagnose breast cancer?

No, Cancer Marker Female is a panel of tumour markers that provides supportive information. It should be interpreted alongside clinical assessment, imaging and other relevant investigations.

Is CA 15.3 a breast cancer screening test?

No. CA 15.3 is not recommended as a routine screening test for people without symptoms. It may be used in selected people already diagnosed with breast cancer to monitor the disease, together with clinical assessment and imaging.

What is an FNAC test for a breast lump?

FNAC uses a thin needle to collect cells from a lump or suspicious area. A pathologist examines them to provide information that can guide further evaluation.

Who should consider a BRCA gene test?

People with relevant personal or family histories, or other features suggesting hereditary breast or ovarian cancer risk. Genetic counselling can help decide whether testing is appropriate.